A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

December 13, 2024

Study Completion Date

January 9, 2025

Conditions

GoutHyperuricemia

Interventions

DRUG

Febuxostat

Tablets, Once a day (QD), Per oral

DRUG

IBI128

Other Names: LC350189, Tigulixostat,Tablets, Once a day (QD), Per oral

Trial Locations (1)

Shanghai Fudan University HuaShan Hospital, Shanghai

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT06501534 - A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects | Biotech Hunter | Biotech Hunter